Masashi Fujii

机构：Tottori University Hospital · ORCID：0000-0002-2490-1271

发表论文 96 篇 · 总被引 574 次 · h-index 14

代表论文

• Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08 (2020 · British Journal of Cancer · 被引 48)
• Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial (2023 · European Journal of Cancer · 被引 22)
• Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09 (2021 · Targeted Oncology · 被引 22)
• Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial (2024 · Nature Communications · 被引 17)
• Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial) (2019 · Radiotherapy and Oncology · 被引 16)
• The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13). (2021 · Journal of Clinical Oncology · 被引 14)